Delaware SUPPORT Office Based Opioid Treatment (OBOT) Fellowship - Practice Implementation Track

March 23, 2021 to October 23, 2021

Delaware has the second highest rate of drug overdose in the country; of those overdose deaths, 88% involved opioids. Further, in Delaware, 61 opioid prescriptions are written for every 100 residents. Delaware also ranks first in the country for high-dose and long acting-opioid prescriptions, both of which increase the risk of OUD and overdose. One of the most effective interventions to reduce opioid related mortality is the delivery of evidence-based treatment including medication for opioid use disorder. Like most states, Delaware does not have sufficient treatment capacity for opioid use disorder. Because there are too few addiction medicine specialists, it is critical that primary care, women's health, and infectious disease specialists who are seeing patients in the community increase their confidence and training to be able to identify and treat opioid use disorder. A variety of barriers have been identified as contributors to buprenorphine underutilization including: insufficient training, education and experience; lack of institutional and clinician peer support; poor care coordination; provider stigma; inadequate or burdensome reimbursement; and burdensome regulatory procedures. Increasing office based opioid treatment (OBOT) in Delaware will lead to an increase in access to opioid use disorder treatment. Delaware Medicaid has received a grant from the Center for Medicare and Medicaid Services to improve addiction treatment capacity.

The OBOT Fellowship administrative track is designed to educate administrators on identification of opioid use disorder and process involved with OBOT. We are utilizing self-paced courses as the first component. In addition, the webinars that will be provided over the 6 month period are designed to foster a Delaware based learning collaborative. For the self-paced courses, we are going to touch upon the following topics: Orientation to Substance Use Disorder and Medication for Opioid Use Disorder (MOUD); Team-Based Care for OBOT; Developing external partnerships; and Quality Assurance and Improvement for OBOT.

To increase the number of waivered providers and the buprenorphine prescribing rates among providers accepting Medicaid in Delaware, we will offer an OBOT (office based opioid treatment) Fellowship program that includes tailored training and technical assistance (TA) to Delaware-based 24 administrators and clinicians . The OBOT features an self-paced web-based training followed by a facilitated learning collaborative. The OBOT includes a clinical and administrative track.

Target Audience

This activity is designed for clinic administrators.

Elements of Competence

This CE activity has been designed to improve learner competence and performance and focuses on the American Board of Medical Specialties' areas of patient care and procedural skills and medical knowledge.

This activity focuses on the Interprofessional competencies of roles/responsibilities, interprofessional communication, and teams/teamwork.

This activity also focuses on the Institute of Medicine competencies of provide patient-centered care; work in interdisciplinary teams and employ evidence-based practice.

Learning Objectives

At the conclusion of the activity, the administrative healthcare team members will be able to:

  1. Explain the diagnostic criteria for Substance Use Disorder (SUD) and Medication for Opioid Use Disorder (MOUD)
  2. Describe the administrative tools needed to successfully implement a team-based care for Office-based Opioid Treatment (OBOT) program
  3. Explain the process for implementing a quality assurance and improvement effort for their OBOT program. 
  4. Effectively utilize a Delaware-based learning collaborative to develop external partnerships and support team-based care for OBOT.  
Course summary
Available credit: 
  • 4.25 AMA PRA Category 1 Credit
  • 4.25 ANCC Contact Hours
  • 4.25 University of Wisconsin–Madison Continuing Education Hours
    • 4.25 Approved for AMA PRA Category 1 Credit™
Registration opens: 
03/01/2021
Course expires: 
12/31/2021
Event starts: 
03/23/2021 - 8:00am
Event ends: 
10/23/2021 - 11:59pm
Cost:
$0.00
Rating: 
0
Modules
Group 1
Orientation to Substance Use Disorder (SUD) & Medication for Opioid Use Disorder (MOUD) (Clinical Admin)
Group 2
Team-based care for Office Based Opioid Treatment (OBOT) (Clinical Admin)
Group 3
Partnering with Support Services (Clinical Admin)
Group 4
Quality Assurance and Improvement for OBOT (Clinical Admin)

*The 6 months of Technical Assistance (TA) will occur from April-September 2021.

This is a virtual conference (eastern time). Please see the Program for further information.

A link will be sent to participants prior to the activity start date.

Clinical Director/Planning Committee Chair(s):

Krishna Winfrey, BS, Principal Researcher

Maliha Ali, MBBS, DrPH, Researcher

Quy Nhi Cap, MPH, Researcher

Daniel Harwell, MS, Researcher

Sarah Mossburg, BSN, MS, PhD, Researcher

Elizabeth Salisbury-Afshar,MD, MPH, FAAFP, FACPM, DFASAM

Mishka Terplan, MD MPH FACOG DFASAM

Claire Viscione, BS, Research Assistant

 

Additional Committee Members:

Anika Alvanzo, MD, Physician

Amanda Brooks, LCSW CADC, Licensed Clinical Social Worker and Certified Alcohol and Drug Counselor

Kathryn Basques, MSW MSN, APN, PMHMP-BC, Nurse Practitioner

Megan Buresh, MD, Physician

Nicole Michele Gastala, MD, Physician

Terry Horton, MD, FACP, DABAM, Physician
 

POLICY ON DISCLOSURE

It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) that the faculty, authors, planners, and other persons who may influence content of this CE activity disclose all relevant financial relationships with commercial interests* in order to allow CE staff to identify and resolve any potential conflicts of interest.  Faculty must also disclose any planned discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). 

For this educational activity, all conflicts of interest have been resolved and detailed disclosures are listed below:

Name

Role

Financial Relationship Disclosures

Discussion of Unlabeled/Unapproved uses of drugs/devices in presentation?

Maliha Ali, MBBS, DrPHCommittee memberNo relevant financial relationships to discloseNo
Anika Alvanzo, MDSpeaker/AuthorAmerican Society of Addiction Medicine (Fiduciary Officer), Maryland Department of Health and Mental Hygiene (Contractor); Pyramid Healthcare, Inc. (Employment)No
Terese Bailey, BSPlannerNo relevant financial relationships to discloseNo
Kathryn Basques, MSW, MSN, APN, PMHMP-BCSpeaker/AuthorNo relevant financial relationships to discloseYes
Amanda Brooks, LCSW, CADCSpeaker/AuthorNo relevant financial relationships to discloseNo
Megan Buresh, MDSpeaker/AuthorAmerican Society of Addiction Medicine (Contractor)No
Quy Nhi Cap, MPHCommittee Member & PlannerNo relevant financial relationships to discloseNo
Nicole Gastala, MDSpeaker/AuthorNo relevant financial relationships to discloseNo
Daniel Harwell, MSCommittee MemberNo relevant financial relationships to discloseNo
Terry Horton, MD, FACP, DABAMCommittee MemberMasimo (Consultant and Advisory Group Member)No
Sarah Mossburg, BSN, MS, PhDCommittee MemberNo relevant financial relationships to discloseNo
Elizabeth Salsbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAMCommittee Member, Speaker/Author, Content ReviewerNo relevant financial relationships to discloseNo
Mishka Terplan, MD, MPH, FACOG, DFASAMCommittee Member, Speaker/Author, Content ReviewerNo relevant financial relationships to discloseNo
Claire Viscione, BSCommittee MemberNo relevant financial relationships to discloseNo
Krishna Winfrey, BSCommittee MemberNo relevant financial relationships to discloseNo

*The ACCME defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Discloser List CME Internal Report

Accreditation Statement

Jointly Accredited Provider LogoIn support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) and the American Institutes for Research (AIR). The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation Statements

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of X.XX AMA PRA Category 1 CreditsPhysicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of X.X ANCC contact hours.  ANCC pharmacotherapeutic contact hours will be calculated and awarded as appropriate to meet the needs of advanced practice nurses.

The University of Wisconsin–Madison School of Nursing is Iowa Board of Nursing provider 350. Iowa Board of Nursing accepts ANCC contact hours for nursing continuing education requirements.

Continuing Education Units (CEUs)

The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.XX continuing education units (CEUs) or X.XX hours. 

 

Jointly Provided by:
The American Institutes for Research (AIR)

University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP)

Available Credit

  • 4.25 AMA PRA Category 1 Credit
  • 4.25 ANCC Contact Hours
  • 4.25 University of Wisconsin–Madison Continuing Education Hours
    • 4.25 Approved for AMA PRA Category 1 Credit™

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

Free, current version of Chrome, Firefox, Safari, or Edge. Some older browsers and Internet Explorer could produce error messages or not display the content correctly. Free, current version of Adobe Acrobat Reader or other .pdf reader